世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

がん診断におけるAI市場(コンポーネント:ソフトウェアソリューションとサービス;癌タイプ:乳がん、前立腺がん、肺がん、大腸がん、子宮頸がん、その他) - 世界の産業分析、規模、シェア、成長、動向、予測、2023年~2031年


AI in Cancer Diagnostics Market (Component: Software Solutions and Services; Cancer Type: Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

がん診断におけるAI市場 - レポートの範囲 TMR社のがん診断用AIの世界市場に関する調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2023年8月17日 US$5,795
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
153 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

がん診断におけるAI市場 - レポートの範囲
TMR社のがん診断用AIの世界市場に関する調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。当レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界のがん診断におけるAI市場の収益を提供しています。また、2023年から2031年までの世界のがん診断におけるAI市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、がん診断用AI市場を理解しました。

二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれる。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界のがん診断用AI市場の様々な属性を調査した。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界のがん診断におけるAI市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界のがん診断におけるAI市場への参入に関心のある企業にとっても貴重なツールとなります。

当レポートでは、世界のがん診断用AI市場の競争環境について掘り下げています。世界のがん診断用AI市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性の観点からプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートでプロファイリングされた世界のがん診断におけるAI市場におけるプレイヤーの属性である。

がん診断用AIの世界市場レポートが回答した主要な質問
- 予測期間中の全地域におけるがん診断用AIが生み出す売上高/収益は?
- 世界のがん診断におけるAI市場における機会は何か?
- 市場における主な促進要因、阻害要因、機会、脅威は何か?
- 予測期間中に最も速いCAGRで拡大する地域市場はどこか?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは?
- 世界市場で事業を展開する各企業の市場ポジションは?

がん診断におけるAI市場 - 調査目的と調査アプローチ
世界のがん診断におけるAI市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと販売業者、製品の承認に関する規制シナリオについて詳細に解説しています。

本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。

本レポートでは、世界のがん診断におけるAI市場を製品、エンドユーザー、地域の観点から分析している。各基準における主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載している。このような貴重な洞察により、市場関係者は世界のがん診断におけるAI市場への投資について、情報に基づいたビジネス上の意思決定を行うことが可能になります。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global AI in Cancer Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Component Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global AI in Cancer Diagnostics Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Different Technique Overview of Machine Learning in Oncology
    5.2. Technological Advancements
    5.3. List of Major Software used as AI in Cancer Diagnostics
    5.4. Regulatory Scenario by Region/Globally
    5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Component
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Component, 2017-2031
        6.3.1. Software Solutions
        6.3.2. Services
    6.4. Market Attractiveness Analysis, by Component
7. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Cancer Type, 2017-2031
        7.3.1. Breast Cancer
        7.3.2. Prostate Cancer
        7.3.3. Lung Cancer
        7.3.4. Colorectal Cancer
        7.3.5. Cervical Cancer
        7.3.6. Others
    7.4. Market Attractiveness Analysis, by Cancer Type
8. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Application
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Application, 2017-2031
        8.3.1. Screening & Diagnosis
        8.3.2. Tumor Identification
        8.3.3. Monitoring
    8.4. Market Attractiveness Analysis, by Application
9. Global AI in Cancer Diagnostics Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Hospitals
        9.3.2. Diagnostic Centers
        9.3.3. Medical Research Institutes
        9.3.4. Contract Research Organizations
    9.4. Market Attractiveness Analysis, by End-user
10. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017-2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America AI in Cancer Diagnostics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Component, 2017-2031
        11.2.1. Software Solutions
        11.2.2. Services
    11.3. Market Value Forecast, by Cancer Type, 2017-2031
        11.3.1. Breast Cancer
        11.3.2. Prostate Cancer
        11.3.3. Lung Cancer
        11.3.4. Colorectal Cancer
        11.3.5. Cervical Cancer
        11.3.6. Others
    11.4. Market Value Forecast, by Application, 2017-2031
        11.4.1. Screening & Diagnosis
        11.4.2. Tumor Identification
        11.4.3. Monitoring
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Hospitals
        11.5.2. Diagnostic Centers
        11.5.3. Medical Research Institutes
        11.5.4. Contract Research Organizations
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Component
        11.7.2. By Cancer Type
        11.7.3. By Application
        11.7.4. By End-user
        11.7.5. By Country
12. Europe AI in Cancer Diagnostics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Component, 2017-2031
        12.2.1. Software Solutions
        12.2.2. Services
    12.3. Market Value Forecast, by Cancer Type, 2017-2031
        12.3.1. Breast Cancer
        12.3.2. Prostate Cancer
        12.3.3. Lung Cancer
        12.3.4. Colorectal Cancer
        12.3.5. Cervical Cancer
        12.3.6. Others
    12.4. Market Value Forecast, by Application, 2017-2031
        12.4.1. Screening & Diagnosis
        12.4.2. Tumor Identification
        12.4.3. Monitoring
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Hospitals
        12.5.2. Diagnostic Centers
        12.5.3. Medical Research Institutes
        12.5.4. Contract Research Organizations
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Component
        12.7.2. By Cancer Type
        12.7.3. By Application
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific AI in Cancer Diagnostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Component, 2017-2031
        13.2.1. Software Solutions
        13.2.2. Services
    13.3. Market Value Forecast, by Cancer Type, 2017-2031
        13.3.1. Breast Cancer
        13.3.2. Prostate Cancer
        13.3.3. Lung Cancer
        13.3.4. Colorectal Cancer
        13.3.5. Cervical Cancer
        13.3.6. Others
    13.4. Market Value Forecast, by Application, 2017-2031
        13.4.1. Screening & Diagnosis
        13.4.2. Tumor Identification
        13.4.3. Monitoring
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Hospitals
        13.5.2. Diagnostic Centers
        13.5.3. Medical Research Institutes
        13.5.4. Contract Research Organizations
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Component
        13.7.2. By Cancer Type
        13.7.3. By Application
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America AI in Cancer Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Component, 2017-2031
        14.2.1. Software Solutions
        14.2.2. Services
    14.3. Market Value Forecast, by Cancer Type, 2017-2031
        14.3.1. Breast Cancer
        14.3.2. Prostate Cancer
        14.3.3. Lung Cancer
        14.3.4. Colorectal Cancer
        14.3.5. Cervical Cancer
        14.3.6. Others
    14.4. Market Value Forecast, by Application, 2017-2031
        14.4.1. Screening & Diagnosis
        14.4.2. Tumor Identification
        14.4.3. Monitoring
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Hospitals
        14.5.2. Diagnostic Centers
        14.5.3. Medical Research Institutes
        14.5.4. Contract Research Organizations
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Component
        14.7.2. By Cancer Type
        14.7.3. By Application
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa AI in Cancer Diagnostics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Component, 2017-2031
        15.2.1. Software Solutions
        15.2.2. Services
    15.3. Market Value Forecast, by Cancer Type, 2017-2031
        15.3.1. Breast Cancer
        15.3.2. Prostate Cancer
        15.3.3. Lung Cancer
        15.3.4. Colorectal Cancer
        15.3.5. Cervical Cancer
        15.3.6. Others
    15.4. Market Value Forecast, by Application, 2017-2031
        15.4.1. Screening & Diagnosis
        15.4.2. Tumor Identification
        15.4.3. Monitoring
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Hospitals
        15.5.2. Diagnostic Centers
        15.5.3. Medical Research Institutes
        15.5.4. Contract Research Organizations
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Component
        15.7.2. By Cancer Type
        15.7.3. By Application
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix, by tier and size of companies
    16.2. Market Share Analysis, by Company, 2022
    16.3. Company Profiles
        16.3.1. Ibex Medical Analytics
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. EarlySign
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Cancer Center.ai
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Microsoft
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Flatiron
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Path AI
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Therapixel
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Tempus
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Paige AI, Inc.
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Kheiron Medical Technologies Limited
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. SkinVision
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Freenome
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview
        16.3.13. Whiterabbit.ai
            16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.13.2. Product Portfolio
            16.3.13.3. Financial Overview
            16.3.13.4. SWOT Analysis
            16.3.13.5. Strategic Overview
        16.3.14. Mindpeak GmbH
            16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.14.2. Product Portfolio
            16.3.14.3. Financial Overview
            16.3.14.4. SWOT Analysis
            16.3.14.5. Strategic Overview

 

ページTOPに戻る


 

Summary

AI in Cancer Diagnostics Market – Scope of Report
TMR’s report on the global AI in cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global AI in cancer diagnostics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global AI in cancer diagnostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the AI in cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global AI in cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global AI in cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global AI in cancer diagnostics market.

The report delves into the competitive landscape of the global AI in cancer diagnostics market. Key players operating in the global AI in cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global AI in cancer diagnostics market profiled in this report.

Key Questions Answered in Global AI in Cancer Diagnostics Market Report
• What is the sales/revenue generated by AI in cancer diagnostics across all regions during the forecast period?
• What are the opportunities in the global AI in cancer diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

AI in Cancer Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global AI in cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global AI in cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global AI in cancer diagnostics market.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global AI in Cancer Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Component Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global AI in Cancer Diagnostics Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Different Technique Overview of Machine Learning in Oncology
    5.2. Technological Advancements
    5.3. List of Major Software used as AI in Cancer Diagnostics
    5.4. Regulatory Scenario by Region/Globally
    5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Component
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Component, 2017-2031
        6.3.1. Software Solutions
        6.3.2. Services
    6.4. Market Attractiveness Analysis, by Component
7. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Cancer Type, 2017-2031
        7.3.1. Breast Cancer
        7.3.2. Prostate Cancer
        7.3.3. Lung Cancer
        7.3.4. Colorectal Cancer
        7.3.5. Cervical Cancer
        7.3.6. Others
    7.4. Market Attractiveness Analysis, by Cancer Type
8. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Application
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Application, 2017-2031
        8.3.1. Screening & Diagnosis
        8.3.2. Tumor Identification
        8.3.3. Monitoring
    8.4. Market Attractiveness Analysis, by Application
9. Global AI in Cancer Diagnostics Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Hospitals
        9.3.2. Diagnostic Centers
        9.3.3. Medical Research Institutes
        9.3.4. Contract Research Organizations
    9.4. Market Attractiveness Analysis, by End-user
10. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017-2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America AI in Cancer Diagnostics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Component, 2017-2031
        11.2.1. Software Solutions
        11.2.2. Services
    11.3. Market Value Forecast, by Cancer Type, 2017-2031
        11.3.1. Breast Cancer
        11.3.2. Prostate Cancer
        11.3.3. Lung Cancer
        11.3.4. Colorectal Cancer
        11.3.5. Cervical Cancer
        11.3.6. Others
    11.4. Market Value Forecast, by Application, 2017-2031
        11.4.1. Screening & Diagnosis
        11.4.2. Tumor Identification
        11.4.3. Monitoring
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Hospitals
        11.5.2. Diagnostic Centers
        11.5.3. Medical Research Institutes
        11.5.4. Contract Research Organizations
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Component
        11.7.2. By Cancer Type
        11.7.3. By Application
        11.7.4. By End-user
        11.7.5. By Country
12. Europe AI in Cancer Diagnostics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Component, 2017-2031
        12.2.1. Software Solutions
        12.2.2. Services
    12.3. Market Value Forecast, by Cancer Type, 2017-2031
        12.3.1. Breast Cancer
        12.3.2. Prostate Cancer
        12.3.3. Lung Cancer
        12.3.4. Colorectal Cancer
        12.3.5. Cervical Cancer
        12.3.6. Others
    12.4. Market Value Forecast, by Application, 2017-2031
        12.4.1. Screening & Diagnosis
        12.4.2. Tumor Identification
        12.4.3. Monitoring
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Hospitals
        12.5.2. Diagnostic Centers
        12.5.3. Medical Research Institutes
        12.5.4. Contract Research Organizations
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Component
        12.7.2. By Cancer Type
        12.7.3. By Application
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific AI in Cancer Diagnostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Component, 2017-2031
        13.2.1. Software Solutions
        13.2.2. Services
    13.3. Market Value Forecast, by Cancer Type, 2017-2031
        13.3.1. Breast Cancer
        13.3.2. Prostate Cancer
        13.3.3. Lung Cancer
        13.3.4. Colorectal Cancer
        13.3.5. Cervical Cancer
        13.3.6. Others
    13.4. Market Value Forecast, by Application, 2017-2031
        13.4.1. Screening & Diagnosis
        13.4.2. Tumor Identification
        13.4.3. Monitoring
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Hospitals
        13.5.2. Diagnostic Centers
        13.5.3. Medical Research Institutes
        13.5.4. Contract Research Organizations
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Component
        13.7.2. By Cancer Type
        13.7.3. By Application
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America AI in Cancer Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Component, 2017-2031
        14.2.1. Software Solutions
        14.2.2. Services
    14.3. Market Value Forecast, by Cancer Type, 2017-2031
        14.3.1. Breast Cancer
        14.3.2. Prostate Cancer
        14.3.3. Lung Cancer
        14.3.4. Colorectal Cancer
        14.3.5. Cervical Cancer
        14.3.6. Others
    14.4. Market Value Forecast, by Application, 2017-2031
        14.4.1. Screening & Diagnosis
        14.4.2. Tumor Identification
        14.4.3. Monitoring
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Hospitals
        14.5.2. Diagnostic Centers
        14.5.3. Medical Research Institutes
        14.5.4. Contract Research Organizations
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Component
        14.7.2. By Cancer Type
        14.7.3. By Application
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa AI in Cancer Diagnostics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Component, 2017-2031
        15.2.1. Software Solutions
        15.2.2. Services
    15.3. Market Value Forecast, by Cancer Type, 2017-2031
        15.3.1. Breast Cancer
        15.3.2. Prostate Cancer
        15.3.3. Lung Cancer
        15.3.4. Colorectal Cancer
        15.3.5. Cervical Cancer
        15.3.6. Others
    15.4. Market Value Forecast, by Application, 2017-2031
        15.4.1. Screening & Diagnosis
        15.4.2. Tumor Identification
        15.4.3. Monitoring
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Hospitals
        15.5.2. Diagnostic Centers
        15.5.3. Medical Research Institutes
        15.5.4. Contract Research Organizations
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Component
        15.7.2. By Cancer Type
        15.7.3. By Application
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix, by tier and size of companies
    16.2. Market Share Analysis, by Company, 2022
    16.3. Company Profiles
        16.3.1. Ibex Medical Analytics
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. EarlySign
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Cancer Center.ai
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Microsoft
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Flatiron
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Path AI
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Therapixel
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Tempus
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Paige AI, Inc.
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Kheiron Medical Technologies Limited
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. SkinVision
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Freenome
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview
        16.3.13. Whiterabbit.ai
            16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.13.2. Product Portfolio
            16.3.13.3. Financial Overview
            16.3.13.4. SWOT Analysis
            16.3.13.5. Strategic Overview
        16.3.14. Mindpeak GmbH
            16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.14.2. Product Portfolio
            16.3.14.3. Financial Overview
            16.3.14.4. SWOT Analysis
            16.3.14.5. Strategic Overview

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Transparency Market Research社の医療分野での最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る